Story

On air. The free wire runs 15 minutes behind live. See pricing

World, crypto, finance and tech news, scored for impact.

MarketsSEC EDGAR SCHEDULE 13GFiled 14 h ago

4D Molecular Therapeutics, Inc.: BIOTECHNOLOGY VALUE FUND L P amends Schedule 13G stake filing

Open the sourceReported by SEC EDGAR SCHEDULE 13G, sec.gov, 16 November 2026, by SEC EDGAR SCHEDULE 13G

Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.

Biotechnology Value Fund L.P. filed an amended Schedule 13G with the SEC (accession 0000921895-26-003177) updating its beneficial ownership stake in 4D Molecular Therapeutics, Inc. The filing signals a change in the institutional investor's position in the clinical-stage gene therapy developer. The amendment's details on the exact size and direction of the stake change were not disclosed in the headline. Investors will watch for the updated ownership percentage and any subsequent 13F or 13G filings for further clarity on the fund's conviction.

Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.

Named in this story

4D Molecular Therapeutics, Inc., BIOTECHNOLOGY VALUE FUND L P